Showing 3141-3150 of 5956 results for "".
- Takeda Nears Deal to Buy Shire in Its Biggest Purchasehttps://modernod.com/news/takeda-nears-deal-to-buy-shire-in-its-biggest-purchase/2480167/Takeda Pharmaceutical is nearing an agreement to buy rival drugmaker Shire, people familiar with the matter said, according to a report in Bloomberg. The deal, if appr
- Hoya Achieves CE Mark for 4-in-1 Multisert Preloaded Delivery System with Vivinex IOLhttps://modernod.com/news/hoya-achieves-ce-mark-for-4-in-1-multisert-preloaded-delivery-system-with-vivinex-iol/2480171/Hoya Surgical Optics has obtained European CE Mark for the Vivinex IOL with the new multiSert 4-in-1 preloaded delivery system. MultiSert offers cataract surgeons control in the palm of their hands as they now have the option of using either a two-handed screw or a one-handed technique while impl
- Optos Unveils Monaco Ultra-Widefield Imaging Device with OCT Capabilitieshttps://modernod.com/news/optos-unveils-monaco-ultra-widefield-imaging-device-with-oct-capabilities/2480175/Optos has announced that Monaco, which the company describes as the first ultra-widefield imaging device combined with OCT, was launched Thursday in the United States. Monaco is a compact desk-top UWF retinal imaging device that provides greater imaging functionality and expands the compan
- OWL: Advancing Diversity in Leadership Appoints New Executive Director, Gaynor Frieshttps://modernod.com/news/owl-advancing-diversity-in-leadership-appoints-new-executive-director-gaynor-fries/2480180/OWL: Advancing Diversity in Leadership announced that Gaynor Fries has been appointed Executive Director of the organization. Gaynor has been a key part of the support team behind OWL since July 2015. With a BA in Business Administration and a Certificate in Non-Profit Management from Duke
- Visulytix’s AI Tool Equivalent to Human Experts in Glaucoma Detectionhttps://modernod.com/news/visulytixs-ai-tool-equivalent-to-human-experts-in-glaucoma-detection/2480181/Visulytix announced that Pegasus-disc, its artificial intelligence (AI) decision support tool for the analysis of retinal images, has been shown to perform similarly to the consensus opinion of human experts when detecting glaucoma from optic disc images. This follows a study conducted on the ima
- New Novartis Phase 3 Data for Brolucizumab Demonstrate Reliability of 12-Week Treatment Intervalhttps://modernod.com/news/new-novartis-phase-3-data-for-brolucizumab-demonstrate-reliability-of-12-week-treatment-interval/2480190/Novartis announced new positive brolucizumab (RTH258) data in neovascular age-related macular degeneration (AMD) from a prespecified secondary analysis of the phase 3 HAWK and HARRIER trials. The findings showed that patients assessed as appropriate for a 12-week treatment frequency during
- Allergan CEO: Large Deal Would Be An Unlikely Outcome of Reviewhttps://modernod.com/news/allergan-ceo-large-deal-would-be-an-unlikely-outcome-of-review/2480196/Allergan Chief Executive Brent Saunders said on Monday that while the company is considering large, transformational deals as part of a strategic review, they are a “very low priority and a very unlikely outcome” of the process, according to a Reuters
- MeiraGTx Announces AAV-RPGR Granted Fast Track Designation by FDA for Treatment of X-Linked Retinitis Pigmentosa Due to RPGR Deficiencyhttps://modernod.com/news/meiragtx-announces-aav-rpgr-granted-fast-track-designation-by-fda-for-treatment-of-x-linked-retinitis-pigmentosa-due-to-rpgr-deficiency/2480212/MeiraGTx Limited, a clinical stage gene therapy company, announced that the FDA has granted Fast Track designation for AAV-RPGR for the treatment of X-linked retinitis pigmentosa (XLRP) due to defects in the retinitis pigmentosa GTPase regulator (RPGR) gene. “XLRP is a devastating c
- Akorn Asks Delaware Court to Require Fresenius Kabi to Fulfill Its Obligations Under Merger Agreementhttps://modernod.com/news/akorn-asks-delaware-court-to-require-fresenius-kabi-to-fulfill-its-obligations-under-merger-agreement/2480214/Akorn filed a complaint in Delaware Chancery Court asking that Fresenius Kabi AG be required to fulfill its obligations under the definitive merger agreement, and issued the following statement: “Fresenius’ attempt to terminate the transaction on the pretext that the findings from the ongo
- Camras Vision Announces Completion of $5.7 Million Financing for Novel Glaucoma Devicehttps://modernod.com/news/camras-vision-announces-completion-of-5-7-million-financing-for-novel-glaucoma-device/2480215/Camras Vision has closed on $5.7 million in equity funding to be used to support four clinical trials globally, including a pilot study in the United States, to study the efficacy of the Camras device for the treatment of refractory glaucoma. The funding was made in its